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Abstract  29 
Background & Aims: The role of enteral nutrition (EN) fat composition in regulating 30 
inflammation in Crohn’s disease (CD) is not clear.  There is, moreover, insufficient evidence 31 
to guide the choice of EN in CD with any confidence.  We have reanalysed the findings of 32 
previous studies in a systematic review focusing on the relationship between EN fat content 33 
and remission rates (RR). 34 
Methods: A systematic search with no language restriction was undertaken in Medline and 35 
Embase databases supplemented by a manual search in the reference lists of identified 36 
studies.  The selection criteria were: clinical trial, exclusive EN, adults and CD.  Data on the 37 
type of EN, its fat composition, achieved RR, and study design were extracted. An 38 
established assessment tool was used to assess the quality of the studies. 39 
Results: A total of 29 clinical trials are included in this review. The quality of the studies was 40 
highly variable. No fewer than 27 formulations of enteral feed were identified including 4 41 
elemental and 23 non-elemental preparations.  42 
There was a positive correlation between the total n-6 fatty acid content and response rates, 43 
which was significant when expressed as the ratio between n-6 and n-3 fatty acids (r= 0.378, 44 
p = 0.018).  A non-significant positive trend was founded (r = 0.072; p = 0.643) between 45 
medium chain triglycerides (MCT) delivery as a percentage of the total energy provision and 46 
RR.  While a non-significant negative trend was reported for the delivery of monounsaturated 47 
fatty acids (MUFA) (r = -0.23, p = 0.13). A qualitative advantage to regimens based on 48 
safflower oil suggest that optimised therapeutic approaches are within reach. 49 
 50 
Keywords: Crohn's disease, Enteral nutrition, Lipid, Fatty acid, Dietary fat, and 51 
Inflammatory bowel disease  52 
 53 
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 55 
Abbreviations 56 
EN: Enteral nutrition 57 
CD: Crohn’s disease 58 
RR: Remission rate 59 
TGF-β: Transforming growth factor-β 60 
MCT: Medium chain triglycerides 61 
LCT: Long chain triglycerides 62 
MUFA: Monounsaturated fatty acid 63 
PUFA: Polyunsaturated fatty acid 64 
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Introduction 77 
Crohn's disease (CD) remains an incompletely understood, inflammatory condition of 78 
the intestine.  Although there are important genetic components to its origins, there are also 79 
undoubted environmental elements, amongst which dietary factors are clearly identifiable.  80 
As well as having a probable role in pathogenesis, nutrition has been identified as a key 81 
mediator in established disease, such that, in paediatrics at least, defined enteral nutrition 82 
(EN) is the treatment of first choice for many patients.  However, as is often the case in 83 
clinical nutrition, the evidence base is not as strong as might be wished.  Several meta-84 
analyses have been conducted, but it remains difficult to judge the true effectiveness of EN in 85 
patients with CD.  The collected evidence supports a superior effect of corticosteroids over 86 
EN in adults with CD, but many adult clinicians and most paediatricians believe that EN is an 87 
appropriate and evidence-based primary therapy in CD.  This belief rests on the positive 88 
results from studies of paediatric and malnourished CD patients, which confirm beneficial 89 
effects of EN in improving growth and nutritional status, but which also indicate mucosal 90 
healing, and of course a favourable risk profile compared to pharmacological options.   91 
Enteral nutrition comprises, however, a broad range of options, and the limited 92 
comparative evidence prevents confidence that the best choice(s) can currently be made.  93 
Polymeric, protein-based feeds with high fat content have been compared with low fat, 94 
glucose and amino acid-based feeds, and with oligomeric peptide-based feeds [1-4], but 95 
without compelling evidence that one is better than another [4].  At present a single EN 96 
formula is licenced and marketed specifically for inflammatory bowel disease in adults.  This 97 
is a casein-based polymeric feed rich in transforming growth factor-β (TGF-β), but there is 98 
little evidence to support any particular efficacy [5, 6].  99 
Meta-analysis shows a weak and non-significant positive association between the 100 
protein content of feeds and their associated clinical response rates (RR).  One meta-analysis 101 
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found a negative correlation between long chain triglyceride (LCT) content and RR [7], and a 102 
second found comparable but non-significant trends favouring low LCT and low overall fat 103 
content [4]. Given the potential aetiopathogenic relevance of lipids to Crohn's disease (more 104 
disease in populations on high fat Western diets) and the curious phenomenon of fat 105 
wrapping (almost pathognomonic of Crohn's), further investigation in this area appears 106 
readily justifiable despite and partly because of the inability of the other meta-analyses to 107 
provide a verdict on this issue.  108 
The aim of this systematic review has been to reanalyse the findings of the older 109 
studies and to combine these with the findings of those more recently published, specifically 110 
to evaluate the relationship between nutrient fat content and response rates in the treatment of 111 
patients with CD.  Conscious that currently reported evidence is inconclusive and aware that 112 
many authorities consider the case for EN so weak as to argue robustly against it in the 113 
treatment of CD, we have approached this in a different and we hope more exploratory 114 
fashion than previous reviews.  We focus on specific fatty acids, not just on lipid class, and 115 
on the ratios of individual fatty acids to each other, as well as to other macronutrients and to 116 
their relative contributions to energy provision. 117 
Materials and methods 118 
The PRISMA checklist and guidelines were used for this systematic review (see 119 
supplementary data in Appendix A). The study is registered with the PROSPERO database 120 
of systematic reviews, registration number: CRD42016033857. 121 
Search strategy  122 
A computer-based systematic search was undertaken using the Medline database 123 
(1946 to present) and the Embase database via OVID.  The search strategy was customized 124 
for each database and applied to titles and abstracts of papers.  For text terms related to 125 
enteral nutrition we used: “enteral”, “elemental”, “polymeric”, “whole protein”, “amino acid 126 
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based”, “peptide based”, “low fat”, or “high fat”; these terms were all combined with 127 
“nutrition”, “feeding”, “diet”, or “feed”.  For disease-related text terms we used “Crohn’s 128 
disease”, or “inflammatory bowel disease”.  Also, we searched “enteral nutrition” and “Crohn 129 
disease” as index terms (MeSH) and exploded them as appropriate.  The searches were 130 
limited to studies that involved humans, adults (18-plus years), clinical trials, controlled 131 
clinical trials, randomized controlled trials, meta-analyses, and systematic reviews.  The 132 
searches were not restricted to the English language.  In addition, a manual search of the 133 
reference lists of previously published papers was carried out, looking specifically for clinical 134 
trials investigating the effect of EN in adult patients with active CD. 135 
Selection criteria 136 
The selection of studies was determined by two reviewers following set criteria.  The 137 
studies included were required to be prospective clinical trials in adults with CD (including 138 
controlled and uncontrolled trials).  The EN intervention was to have been given exclusively 139 
for a defined period of time without any food intake (only water and sugar/milk-free 140 
beverages were allowed).  The response rate must have been measured as a primary or 141 
secondary outcome, according to clearly stated criteria.  The enteral feed used had to be 142 
clearly defined (i.e. name and type of feed, oil source, and fatty acid composition).  Studies 143 
were removed from consideration if EN was given together with oral food intake, the study 144 
was retrospective, or performed in a paediatric population.  Trials that did not provide a 145 
defined RR for CD, and trials that investigated the effect of EN in combination with other 146 
medical therapies (e.g. with non-absorbable antibiotics or with erythropoietin) were also 147 
excluded.  Studies where the full identity of the lipid content was not published were 148 
excluded only after application to researcher and/or manufacturer had failed to provide this 149 
information.  When studies were published initially as interim reports our analysis used data 150 
only from the later full article. 151 
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Data extraction 152 
For each eligible study, a detailed review was undertaken using a report form, looking 153 
for the type and quantity of fatty acids in the enteral feeds, the RR achieved by EN, which 154 
was calculated on the basis of a “per protocol” analysis, and selected characteristics related to 155 
study design (e.g. duration of intervention, criteria for remission, geographical location, 156 
number of patients).  The gender and age of patients, and the anatomical location and 157 
duration of their disease were recorded.  Any apparent discrepancies in the data extracted 158 
were discussed and resolved between the two reviewers. 159 
Most papers did not provide sufficient detail of the fat composition in the enteral 160 
feeds for our purposes.  These deficits have been addressed as follows.  Where the formula 161 
was described by a proprietary name the manufacturer’s data sheet has been interrogated.  162 
Where no proprietary name was provided a query was sent to the primary investigator of the 163 
study concerned.  In each case our analysis was based on the fatty acid content of the feed 164 
used.  In the great majority of cases this information was not provided either by authors or by 165 
manufacturers.  However, the nature and proportion of the oils in the feeds was generally 166 
available or possible to estimate from the information given.  The fatty acid profile of each 167 
oil was then drawn from a thorough published analysis [8].  One additional and unexpected 168 
problem arose from the fact that the composition of some feeds has been modified within the 169 
last fifteen years.  Care was therefore taken to ensure that the analysis of the lipid content 170 
referred to that of the feed available at the time of the study. 171 
Quality assessment   172 
The quality of the included studies was judged according to the Downs and Black 173 
quality checklist on reporting, external validity, internal validity (study bias), and 174 
confounding (selection bias) [9], with Livingston’s amendment for assessment of power [10].   175 
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This is considered a reliable assessment tool for both randomized and non-randomized 176 
clinical trials: the higher the score the better the quality of the methods.  177 
Data synthesis and statistical analysis 178 
The primary aim of this review has been to review and interpret the available 179 
evidence in order to test the potential correlation between the fat composition of enteral feeds 180 
and the resultant RR.  Scatter plots were used to identify trends.  The significance of possible 181 
relationships was tested by the Pearson correlation test (SPSS Statistics for Windows, 182 
Version 22.0, released 2013. IBM Corp., Armonk, NY, USA). Subgroup analysis was also 183 
conducted which stratified RR by the different levels of fats in EEN feeds (e.g. low vs. 184 
moderate vs. high MCT) and by the different levels of response rate (i.e. low RR <70% vs. 185 
high RR >70% response rate). 186 
Results 187 
Literature search 188 
The electronic searches yielded 63 articles and the manual search from previous meta-189 
analyses and reviews identified an additional 14 articles.  Initial screening of the 77 articles 190 
comprised examination of title and abstract in the context of our selection criteria.  Forty 191 
articles were judged relevant and were further assessed for eligibility.  In each case the full 192 
paper was read (professionally translated if necessary) and checked against our selection 193 
criteria.  Joint decisions on selection were made by the two reviewers, following discussion if 194 
any initial discrepancy arose.  Ultimately our systematic review was based on 29 pertinent 195 
papers (Fig. 1). 196 
Study characteristics 197 
From the total of 29 studies, 24 were controlled trials and 5 were uncontrolled. 198 
Among the controlled trials: 10 compared the efficacy of EN against drug therapy; 2 199 
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compared EN with PN; and 8 investigated the effect of the type of EN by comparing 200 
elemental feeds with non-elemental feeds (which include polymeric and semi-elemental, 201 
oligomeric feeds).  Only 4 trials specifically addressed the effect of fat composition; these 202 
trials compared similar types of feeds but with different fat composition.  The study design, 203 
patient characteristics, and criteria used to measure RR in the papers considered by this 204 
review are provided in Appendix B. 205 
Quality of studies 206 
The quality of the included studies was highly variable.  The study with the highest 207 
quality [11] scored 26 (out of 28) by the assessment tool [9, 10], while the lowest quality 208 
study scored only 10 [12]. Poor (or unknown) representativeness of study subjects and the 209 
lack of power calculations were the commonest defects overall, and in the controlled trials, 210 
there were high risks of performance and detection bias due to the lack of blinding, and high 211 
risk of selection bias due to the lack of allocation concealment during randomization 212 
(Appendix B).  213 
Characteristics of identified enteral feeds 214 
No fewer than 29 distinct enteral feeds have been used in the published studies.  We 215 
have excluded one study [13], and therefore data on two formulae, because patients who were 216 
randomized to receive polymeric feeding were prescribed one or other of the two formulae 217 
depending on availability, but the RR was provided only as a combined rate for the two 218 
formulae.  Therefore, the final number of reviewed formulae is 27: 4 elemental formulae and 219 
23 non-elemental preparations.  The fatty acid composition of these formulae with reference 220 
to RR is demonstrated in Table 1.  More detailed fat composition data are provided in 221 
Appendix B.  222 
Correlation between fat composition and remission rate 223 
Total amount of fat 224 
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Eight studies have compared a pair of feeds with different nutrient composition (e.g. 225 
polymeric versus elemental or semi-elemental versus elemental).  It is difficult to determine 226 
the effect of fat content from these comparisons, as their composition for other nutrients was 227 
not standardised.  Only two studies have specifically examined the effect of the amount of 228 
total fat.  High and low fat feeds (fat mainly in the form of LCT) were compared.  The earlier 229 
study showed that the feed with a low percentage of fats (15.6% of total calories) achieved a 230 
higher RR (92%), than the high fat feed (35.6% of total calories), which achieved a RR of 231 
55% [7]. The later study indicated that a very low fat feed (1.15% of total calories) achieved 232 
a significantly higher RR (80%) than a modest fat feed (11.27% of total calories), which 233 
achieved a RR of (25%) [14].  It will be noted that the amount of fat in this higher fat feed 234 
was barely distinguishable from that of the low fat feed of the earlier study and yet the 235 
clinical effects were hugely different.  Overall we find no significant correlation or trend 236 
between total fat content and RR (r= 0.176, p= 0.252) (Fig. 2A). 237 
Medium chain triglycerides (MCT) 238 
Varying MCT content does not have a consistent strong effect.  A single study which 239 
compared a feed with added MCT against a feed with no MCT, generated significantly 240 
different RRs of 77% and 67% respectively [15].  However, the high MCT feed was semi-241 
elemental and the low MCT feed was elemental, which precludes any firm conclusions about 242 
the contribution of the lipid to the observed differences.  Our quantitative analysis, which is 243 
based on results from all studies, finds a weak non-significant positive trend between MCT 244 
delivery as a percentage of the total energy provision and RR (r = 0.072; p = 0.643) where the 245 
range was from 0 to 30% of total energy supply (Fig. 2B).  The apparent outlier to the upper 246 
left of the plot comes from Leiper’s study [16] in which there was a particularly high 247 
concentration of MCT (>86% of all fat) with a high proportion of MUFA (29%) and a low n-248 
6:n-3 ratio (see below) amongst the fats that were LCTs.  249 
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Long chain triglycerides 250 
The effect of undifferentiated LCTs has been addressed by comparing feeds with 251 
similar amounts of total fat but with different percentages of LCT. One study (already 252 
mentioned above) compared four feeds: elemental, elemental with added LCT, elemental 253 
with added MCT, and semi-elemental [7]. The feed with high LCT was associated with the 254 
lowest RR (55%), while the elemental feed with added MCT performed best, with a RR of 255 
92%. However, a second study found no significant difference in RRs between use of feed 256 
with 5% LCT and an isocaloric feed with 30% LCT [16]. Our quantitative analysis of all the 257 
reported studies of all feedings reveals a non-significant negative trend between LCT 258 
provision and RR (r = -0.254; p = 0.096) where the range was from 4 to 35% of total energy 259 
supply and where in most cases the predominant lipids were of the n-6 class (where not, the 260 
relative excess came from n-9 lipid which we also consider disadvantageous (Fig. 2C and see 261 
below). 262 
Saturated fats 263 
No single study has directly compared feeds with different levels of saturated fatty 264 
acids.  We found no significant correlation or trend between the amount of saturated fat and 265 
the RRs (r = -0.007, p = 0.964) where the range was from trace amounts to over 30% of total 266 
energy supply (Fig. 2D). 267 
Olive oil/MUFA 268 
Only a single study has compared two feeds with the same amount of total fat but 269 
with different amounts of oleic acid (balanced by linoleic acid) [11]. The feed with higher 270 
oleic acid content (79% of total fat) was significantly less effective (RR = 27%) than the feed 271 
with lower oleic acid (28%) and higher linoleic acid (45%), which achieved a RR of 63%. 272 
Although there are no other specific studies addressing MUFAs, our overall quantitative 273 
analysis is concordant, showing disadvantage from monounsaturated fatty acids (MUFA) 274 
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with no statistical significance (r = -0.23, p = 0.13) with a range from trace amounts to about 275 
25% of total energy supply (Fig. 2E). 276 
n-6 and n-3 PUFAs 277 
Only the study by Gassull et al. has directly investigated the effect of an n-6-rich feed 278 
(specifically linoleic acid), in which a significantly higher RR was achieved than with a lower 279 
n-6 content [11]. No study of non-elemental formulae readily allows assessment of the 280 
individual effects of an n-3-rich approach.  281 
In our quantitative analysis a very weak non-significant negative correlation was 282 
found between the amount and proportion of PUFA (of all types) and the response rates from 283 
all feeds (r = -0.157, p = 0.308) (Fig. 2F) as was also the case for n-3 fatty acids (r = -0.166, p 284 
= 0.313) (Fig. 2H).  285 
However, there was a weak positive correlation between the total n-6 fatty acid 286 
content and response rates (r = 0.253, NS) (Fig. 2G), statistical significance (r= 0.378, p = 287 
0.018) which remained significant after correction for multiple tests (Fig.2I). In the subgroup 288 
analysis (TABLE 2), when RR was stratified by the level of n-6:n-3, significant difference (p 289 
= 0.011) was reported in the pooled RR between EEN feeds with moderate n-6:n-3 (58.94% 290 
RR) (95% CI 48.99, 68.9) versus feeds with high n-6:n-3 (79.91% RR) (95% CI 72.31, 291 
87.51). 292 
When patients exposed to only a single oil are considered (informal subgroup 293 
analysis) then the use of safflower oil is favoured, with a mean (median) response rate of 294 
83.6% (84%) compared to the overall average response of 68.1% and mean (median) values 295 
for isolated exposure to soybean or arachis oil of 63.7% (68.5%) and 68.6% (75%) 296 
respectively. 297 
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Discussion 298 
The wide range of patient characteristics, the low number of participants in each 299 
study, and varying study designs obstruct the route to confident and generalizable 300 
conclusions.  We deliberately used results taken from observations on patients who followed 301 
treatment protocols (rather than intention to treat), but although biologically justifiable this 302 
will be of limited clinical value if a future “optimal” formula is not tolerated and thus the 303 
treatment plan is not completed.  Fortunately the compliance/acceptance of the many 304 
different formulae did not appear systematically different according to the particular lipid 305 
profiles. This may have been obscured however by the range of duration of the intended 306 
therapies. The duration of intervention in most of the trials examined was between 3 and 8 307 
weeks, 12 weeks in one trial [17], and only 2 weeks in 3 studies [18-20].  308 
No fewer than eight different sets of criteria have been utilised to define response. 309 
Some were strict and binary (e.g. complete steroid withdrawal) and associated with relatively 310 
low response rates [21, 22], while others were more qualitative (subjective).  It should not 311 
have had a major effect on our interpretations since a full analysis performed on this basis 312 
provides the same qualitative results (data not shown). 313 
Our methods may not have been sufficient to overcome bias introduced by the 314 
differing anatomical location of the CD (small bowel, large bowel, or both).  The trials with 315 
the highest proportions of patients with small bowel CD (50% and 52%) also had amongst 316 
the highest RRs (86% and 75% respectively)[21, 23], a linkage already well recognized in the 317 
literature, and perhaps a confounder despite apparently well-matched controls.    318 
It has been thought that EN is more effective in those with early, purely inflammatory 319 
disease.  Although not all evaluated studies provided the duration of the disease, the shortest 320 
and longest mean disease durations (1.3 and 18 years) were associated with similar and very 321 
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respectable RRs of 90% and 80% respectively, suggesting that this effect is not profound [18, 322 
24].  323 
Considerable differences were observed in respect of sex ratio (0-89% male [15], 324 
[25]), but although prognosis of CD may differ between the sexes [25] a systematic bias 325 
could not be detected within our analysis [26].  326 
The divergence between the different types of unsaturated LCTs (n-3, n-6 and n-9) 327 
and outcome appear at first surprising, but are fully consistent with the negative results from 328 
supplementary fish oil in CD [27].  In terms of specific oil content, interpretation is clouded 329 
by the number of feeds which contain multiple oils.  However the numerical advantage to 330 
safflower oil is very much in line with the overall conclusion that high n-6:n-3 ratio is 331 
advantageous and low proportion of MUFA could be relatively effective as well, given the 332 
relative paucity of MUFA in safflower oil (13.9% compared to 23.9% in soy and 56% in 333 
arachis oil) and its n-6:n-3 ratio, which, at over 90, is the highest of all the dietary oils.  It has 334 
been more difficult still to link interpretation to individual fatty acids, but linoleic acid is 335 
favoured, and oleic acid as the only n-9 fatty acid in artificial feeds is targeted for avoidance. 336 
There is a little supportive evidence also for our hypothesised complementary 337 
combination of safflower oil and MCT.  One of the highest response rates in the literature 338 
(92% [7]) was in patients on this combination, and only the study of Lindor et al appears to 339 
point in the opposite direction, this being a small study in which the comparator was steroid 340 
therapy [28]. 341 
Conclusions 342 
The fat content of EN formulae and its influence on controlling the inflammation of 343 
CD has generated interest, but its true role has remained unclear.  Given its potential 344 
importance it is surprising that most authors have not thought it worthwhile or necessary to 345 
disclose the lipid analysis of the formulae used in their study.  This systematic review has 346 
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dissected the previously very broad classification of lipids in order to try to assess the effects 347 
of individual dietary oils and their fatty acids.  It is recognised that definitive analysis is not 348 
possible given, on the one hand, the incomplete comparative information available, and, on 349 
the other, the inevitable complexity introduced by the replacement of one lipid with another 350 
and/or by different total fat content in different feeds.  We manifestly lack sufficiently robust 351 
clinical trials in this area [29]. 352 
However, our results expose significant results from individual studies, and, as well as 353 
several suggestive trends, support significant advantage from a high n-6 to n-3 ratio and 354 
perhaps from avoidance of MUFA.  The various trends are, moreover, not mutually exclusive 355 
despite the considerable variation in study design and response rates.  Aiming for a relatively 356 
low total LCT content and proportionately high MCT content, with a relative low MUFA and 357 
high n-6:n-3 fatty acid ratio can now be argued to offer an optimised approach.  This might 358 
most easily and effectively be achieved by development of feeds based on a combination of 359 
safflower oil and MCT.   360 
 361 
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FIGURE 1: PRISMA 2009 flow diagram demonstrating the search and selection strategy. 
PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. 
Studies included in 
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(n = 29) 
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with reasons 
(n = 11) 
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Records after duplicates removed 
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FIGURE 2: The association between fat composition of enteral nutritional feeds and remission 
rates (calculated based on per protocol analysis) in patients with Crohn’s disease. Pearson 
correlation test was used to measure the strength of the correlation. (A) Total fat percentage (r= -
0.176, P-value= 0.252). (B) Medium chain triglycerides (MCT) percentage (r= 0.072, P-value= 
0.643). (C) Long chain triglycerides (LCT) percentage (r= -0.254, P-value= 0.096). (D) Saturated 
fatty acids (SFA) percentage (r= -0.007, P-value= 0.964). (E) Monounsaturated fatty acids (MUFA) 
percentage (r= -0.23, P-value= 0.13). (F) Polyunsaturated fatty acids (PUFA) percentage (r= -0.157, 
P-value= 0.308). (G) Total linoleic acid (n-6) percentage (r= 0.253, P-value= 0.110). (H) Total 
linolenic acid (n-3) percentage (r= -0.166, P-value= 0.313). (I) Total n-6:n-3 ratio (r= 0.378, P-value= 
0.018*).  
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TABLE 1: Fat composition and remission rate for enteral nutritional formulas 
Reference  Type of enteral nutrition Energy Kcal/day Fat% of total 
calories 
Source of oil LCT% of total 
calories  
LCT% of 
total fat 
MCT% of total 
calories 
MCT% of 
total fat 
SFA% of total 
calories 
SFA% of 
total fat 
MUFA% of total 
calories  
MUFA% of 
total fat 
PUFA% of 
total calories  
PUFA% of 
total fat 
Total n-6% 
of total 
fatty acids 
Total n-3% 
of total 
fatty acids 
n-6:n-3 
Ratio 
RR% 
Bamba et al. (2003)[14] Elemental, Low fat (6 packs of Elental + 
6 packs of dextrin) 
2400 1.15 Soybean oil 1.15 100 0 0 1.19 16.8 0.27 23.9 0.68 59.3 0 7.7 6.70 80 
Elemental, Medium fat (6 packs of 
Elental + 3 packs of dextrin+ 3 packs of 
C-1 dextrin) 
2400 6.21 Soybean oil 6.21 100 0 0 1.04 16.8 1.48 23.9 3.68 59.3 51.6 7.7 6.70 40 
Elemental, High fat (6 packs of Elental + 
6 packs of C-1 dextrin) 
2400 11.27 Soybean oil 11.27 100 0 0 1.89 16.8 2.69 23.9 6.68 59.3 51.6 7.7 6.70 25 
Gassull et al. (2002)[11] Polymeric, high in n-9 MUFA 2307 32 Synthetic Trioleate 30.17 94.28 1.83 5.71 5.16 16.11 25.28 79 2.56 8 6.5 1.5 4.33 27 
Polymeric, high in n-6 PUFA 2266 32 Corn oil 30.17 94.28 1.83 5.71 7.94 24.8 9.02 28.2 14.91 46.6 45 1.6 28.13 63 
Giaffer et al. (1990)[21] Elemental (Vivonex) 2500 1.3 Safflower oil 1.3 100 0 0 0.12 9.1 0.18 13.9 1 77.3 76.5 0.8 95.63 86 
Polymeric (Fortison) 2500 36 Vegetable oil (canola & sunflower) 36 100 0 0 3.74 10.4 15.26 42.4 17.55 48.75 43.6 5.2 8.38 42 
Leiper et al. (2001)[16] Polymeric, 5% LCT - 34.8 Soybean & coconut oils 5 13.8 29.8 86.2 30.69 88.2 1.18 3.4 2.92 8.4 7.4 1 7.40 46 
Polymeric, 30% LCT - 34.8 Palm, Canola, and coconut oils 30 84.7 4.8 15.3 18.72 53.8 12.35 35.5 3.72 10.7 9.5 1.2 7.92 45 
Mansfield et al. (1995)[22] Elemental (E028) 2250 16 Arachis oil 16 100 0 0 2.72 17 8.96 56 4.16 26 20 1 20.00 42 
Semi-elemental (Pepti-2000 LF liquid) 2250 9 Corn (50%) & MCT oils 4.5 50 4.5 50 5.22 58 0.99 11 2.79 31 28.05 0.5 56.10 42 
Middleton et al. (1995)[7] Elemental (E028) - 15.6 Arachis oil 15.6 100 0 0 2.65 17.1 8.88 56.9 4.06 26 20 1 20.00 92 
Elemental (E028), High LCT - 35.6 Safflower & canola oils 35.6 100 0 0 3.95 11.1 23.92 67.2 7.73 21.7 17 4.5 3.78 55 
Elemental (E028), High MCT - 31.6 Safflower, canola, and coconut 
oils 
20.5 64.9 11.1 35.1 13.9 44 13.27 42 4.42 14 11 3 3.67 92 
Semi-elemental (Peptide 2+) - 33.2 Corn & coconut oils 21.6 65 11.6 34.9 21.71 65.4 3.88 11.7 7.6 22.9 22.5 0.4 56.25 87 
Park et al. (1991)[25] Elemental (E028) 2266 16.47 Arachis oil 16.47 100 0 0 3.01 18.3 8.17 49.6 5.07 30.8 30.2 0.4 75.50 50 
Polymeric (Enteral 400) 2289 36 Arachis (75%) & MCT oils 27 75 9 25 14 38.9 13.57 37.7 8.42 23.4 22.9 0.3 76.33 83 
Raouf et al. (1991)[30] Elemental (EO28) - 16.5 Arachis oil 16.5 100 0 0 2.82 17.1 9.39 56.9 4.29 26 20 1 20.00 75 
Polymeric (Triosorbon) - 36 Sunflower (22%) & MCT oils 7.9 22 28.1 78 29.09 80.8 1.76 4.9 5.22 14.5 14.4 0.1 144.00 73 
Rigaud et al. (1991)[13] Elemental (Vivonex HN) 2286 0.8 Safflower oil 0.8 100 0 0 0.07 9.1 0.11 13.9 0.62 77.3 76.5 0.8 95.63 71 
Royall et al. (1994)[23] Elemental (Vivonex-TEN) - 3 Safflower oil 3 100 0 0 0.27 9.1 0.42 13.9 2.32 77.3 76.5 0.8 95.63 84 
Semi-elemental (Peptamen) - 33 Sunflower (30%) & MCT oil 10 30.3 23 69.7 24.37 73.84 2.22 6.72 6.53 19.8 19.68 0.15 131.20 75 
Sakurai et al. (2002)[15] Elemental, Low fat (Elental) - 1.5 Soybean oil 1.5 100 0 0 0.24 15.7 0.36 24.2 0.9 59.8 52.1 7.8 6.68 67 
Semi-elemental, High MCT (Twinline) - 25 Safflower & MCT oil (tricaprilin) 7 28 18 72 18.64 74.54 0.97 3.89 5.41 21.64 21.42 0.22 97.36 77 
Verma et al. (2000)[31] Elemental 2500 17 NS 11.05 65 5.95 35 6.63 39 7.82 46 2.55 15 12  - -  80 
Polymeric 2500 17 NS 11.05 65 5.95 35 6.63 39 7.82 46 2.55 15 12 -  - 67 
Gonzalez-Huix et al. (1993)[32] Polymeric (Edanec HN) 2800 32 Olive oil (55%) & milk fat 27.8 87 4.2 13 13.12 41 13.12 41 5.76 18  -  -  - 80 
Lindor et al. (1992)[28] Semi-elemental (Vital HN) - 9 Safflower (55%) & MCT (45%) 4.95 55 4.05 45 4.68 52.04 1.1 12.32 3.26 36.3 36.08 0.3 120.27 60 
Lochs et al. (1991)[33] Semi-elemental (Peptisorb) - 8 Soybean oil (50%) & MCT 4 50 4 50 4.62 57.85 0.97 12.1 2.39 29.9 26.05 3.9 6.68 60 
Malchow et al. (1990)[34] Semi-elemental (Survimed) - 10 Sunflower 10 100 0 0 1.28 12.8 2.24 22.4 6.6 66 65.6 0.5 131.20 96 
Greenberg et al. (1988)[35] Polymeric (Precision-Isotonic) - 28 Soybean oil 28 100 0 0 4.4 15.7 6.8 24.2 16.7 59.8 52.1 7.8 6.68 58 
Kobayashi et al. (1998)[36] Elemental (Elental) - 1.5 Soybean oil 1.5 100 0 0 0.24 15.7 0.36 24.2 0.9 59.8 52.1 7.8 6.68 70  
Polymeric (Clinimeal) - 28 Corn & coconut oils 19.3 69 8.7 31.15 15 53.7 4.8 17.1 8.23 29.5 28.95 0.55 52.64  67 
Mantzaris et al. (1996)[12] Polymeric (Nutrison HE) - 36 Corn, palm, & coconut oils 34.17 94.92 1.9 5.27 13.45 37.41 11.35 31.54 11.35 31.24 30.63 0.61 50.21 40 
O’moráin et al. (1984)[37] Elemental (Vivonex) - 2.5 Safflower 2.5 100 0 0 0.23 9.1 0.35 13.9 1.9 77.3 76.5 0.8 95.63 100 
Gorard et al. (1993)[38] Elemental (Vivonex TEN) 2100 2.5 Safflower 2.5 100 0 0 0.23 9.1 0.35 13.9 1.9 77.3 76.5 0.8 95.63 77 
Okada et al. (1990)[24] Elemental (Elental) - 1.5 Soybean 1.5 100 0 0 0.24 15.7 0.36 24.2 0.9 59.8 52.1 7.8 6.68 80 
Bodemar et al. (1991)[18] Polymeric (Semper lowfat) - 20 Soybean 20 100 0 0 3 15.7 5 24.2 12 59.8 52.1 7.8 6.68 90 
Coyle and Sladen (1989)[39] Polymeric (Enteral 250) 2000-3000 28 Corn oil 28 100 0 0 4 14.8 8 28.1 16 57.1 56.1 1 56.10 67 
Riordan et al. (1993)[19] Elemental (E028) - 15.6 Arachis oil 15.6 100 0 0 2.82 17.1 9.39 56.9 4.29 26 20 1 20.00 84 
Guo et al. (2013)[40] Polymeric (Nutrison Fiber) 1500-2000 34 Sunflower, canola, & MCT oils 29 84.6 5 15.4 8.7 25.6 19.2 56.4 6.12 18  - - -  85 
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Zoli et al. (1997)[20] Semi-elemental (Peptamen) - 33 Sunflower (30%) & MCT oil 10 30.3 23 69.7 24.37 73.84 2.22 6.72 6.53 19.8 19.68 0.15 131.20 80 
Hu et al. (2014)[17] Semi-elemental (Peptisorb liquid) - 15 Soy oil % MCT oil 7.95 53 7.05 47 8.3 55.3 1.9 12.8 4.8 31.7 27.6 4.1 6.73 71 
Zhu et al. (2013)[41] Polymeric (Nutrison Fibre) 2037 34 Sunflower, canola, & MCT oils 29 84.6 5 15.4 8.7 25.6 19.2 56.4 6.12 18  - -  -  67 
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TABLE 2: Subgrouping analysis for the effect of fat composition of enteral nutritional feeds on CD 
remission rate stratified by the level of lipid class 
Factor assessed Subgroup Number of comparisons (compared 
enteral feeds) 
Pooled RR (95% CI) 
Total fat level Low fat  11 74.09 (63.63, 84.56) 
Moderate fat 21 66.9 (57.53, 76.28) 
High fat 12 64.86 (53.34, 76.38) 
MCT level No MCT 22 69.59 (60.59, 78.59) 
Moderate MCT 10 56.93 (43.8, 70.06) 
High MCT  12 74.83 (67.32, 82.35) 
LCT level  Low LCT 11 74.27 (64.1, 84.45) 
Moderate LCT 22 70.55 (62, 79.09) 
High LCT 11 57.21 (45.35, 69.07) 
SFA level Low SFA 11 77.36 (66.55, 88.18) 
Moderate SFA 22 62.83 (54.36, 71.31) 
High SFA 11 69.55 (57.47, 81.62) 
MUFA level Low MUFA 11 77.45 (70.25, 84.65) 
Moderate MUFA 21 65.29 (56.53, 74.05) 
High MUFA 12 64.61 (50.74, 78.48) 
PUFA level Low PUFA 12 76.83 (70.03, 83.63) 
Moderate PUFA 20 65.17 (56.02, 74.31) 
High PUFA  12 64.42 (50.46, 78.37) 
Total n-6 level Low n-6 11 65.45 (52.23, 78.68) 
Moderate n-6 18 61.11 (51.29, 70.93)* 
High n-6  12 78.83 (70.7, 86.97)* 
Total n-3 level Low n-3  10 72.3 (60.26, 84.34) 
Moderate n-3 19 67.84 (58.07, 77.62) 
High n-3 10 60.7 (45.96, 75.44) 
n-6:n-3 level Low n-6:n-3 10 67.9 (54.06, 81.74) 
Moderate n-6:n-3 18 58.94 (48.99, 68.9)* 
High n-6:n-3 11 79.91 (72.31, 87.51)* 
-Low level (lower quartile range); moderate level (interquartile range); high level (upper quartile range). 
-RR (remission rate); MCT (medium chain triglycerides); LCT (long chain triglycerides); SFA (saturated fatty acids); MUFA (monounsaturated fatty acids); 
PUFA (polyunsaturated fatty acids). 
-One-way ANOVA with multiple correction test have been used to test the significance of difference in RR between the subgroups. 
*Difference between subgroups is significant (P-value<0.05). 
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TABLE 3: Subgrouping analysis for the correlation between the fat composition of enteral nutritional 
feeds and CD remission rate stratified by the level of remission rates achieved 
Factor assessed Subgroup Number of 
comparisons 
(compared enteral 
feeds) 
r (95% CI) P-value 
RR for total fat correlation Low RR < 70% 20 -0.03 (-0.46, 0.42) 0.91 
High RR ≥ 70% 24 -0.00 (-0.41, 0.40) 0.99 
RR for MCT correlation  Low RR < 70% 20 0.05 (-0.39, -0.48) 0.83 
High RR ≥ 70% 24 -0.28 (-0.62, 0.14) 0.18 
RR for LCT correlation Low RR < 70% 20 -0.05 (-0.49, 0.39) 0.81 
High RR ≥ 70% 24 0.27 (-0.15, 0.60) 0.21 
RR for SFA correlation Low RR < 70% 20 -0.00 (-0.44, 0.44) >0.99 
High RR ≥ 70% 24 -0.21 (-0.57, 0.21) 0.32 
RR for MUFA correlation Low RR < 70% 20 -0.16 (-0.56, 0.31) 0.51 
High RR ≥ 70% 24 0.23 (-0.19, 0.58) 0.29 
RR for PUFA correlation Low RR < 70% 20 0.13 (-0.33, 0.54) 0.57 
High RR ≥ 70% 24 0.24 (-0.18, 0.59) 0.26 
RR for n-6 correlation Low RR < 70% 19 0.19 (-0.29, 0.59) 0.44 
High RR ≥ 70% 22 0.19 (-0.26, 0.56) 0.41 
RR for n-3 correlation Low RR < 70% 18 -0.08 (-0.53, 0.39) 0.74 
High RR ≥ 70% 21 -0.13 (-0.53, 0.32) 0.59 
RR for n-6:n-3 correlation  Low RR < 70% 18 0.30 (-0.19, 0.67) 0.22 
High RR ≥ 70% 21 -0.01 (-0.44, 0.43) 0.98 
-r (Pearson correlation coefficient) 
-RR (remission rate); MCT (medium chain triglycerides); LCT (long chain triglycerides); SFA (saturated fatty acids); MUFA (monounsaturated fatty acids); 
PUFA (polyunsaturated fatty acids). 
 
